KRAS and neoplasm: RMC-6236 combined cyclophilin A (CYPA) to target KRAS in an active state, forming a tri-complex that inhibited downstream signal transduction.72 Preclinical results suggested that RMC-6236 down-regulated RAS signaling, leading to tumor regression in the mouse xenograft model.73 Clinical trials are ongoing to evaluate RMC-6236 as a monotherapy and in combination with immune checkpoint inhibitors (NCT05379985, NCT06162221).